Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more
Laurus Labs Limited - Asset Resilience Ratio
Laurus Labs Limited (LAURUSLABS) has an Asset Resilience Ratio of 0.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Laurus Labs Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Laurus Labs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹633.80 Million | 0.67% |
| Short-term Investments | ₹63.40 Million | 0.07% |
| Total Liquid Assets | ₹697.20 Million | 0.74% |
Asset Resilience Insights
- Limited Liquidity: Laurus Labs Limited maintains only 0.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Laurus Labs Limited Industry Peers by Asset Resilience Ratio
Compare Laurus Labs Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for Laurus Labs Limited (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Laurus Labs Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.57% | ₹528.20 Million | ₹93.36 Billion | +0.33pp |
| 2024-03-31 | 0.23% | ₹195.50 Million | ₹83.87 Billion | -0.15pp |
| 2023-03-31 | 0.38% | ₹294.00 Million | ₹76.60 Billion | +0.06pp |
| 2022-03-31 | 0.32% | ₹222.40 Million | ₹69.68 Billion | -0.36pp |
| 2021-03-31 | 0.68% | ₹390.70 Million | ₹57.51 Billion | +0.68pp |
| 2020-03-31 | 0.00% | ₹880.00K | ₹37.50 Billion | +0.00pp |
| 2019-03-31 | 0.00% | ₹740.00K | ₹33.31 Billion | +2.21pp |
| 2018-03-31 | -2.20% | ₹-664.70 Million | ₹30.17 Billion | +0.24pp |
| 2017-03-31 | -2.44% | ₹-648.62 Million | ₹26.53 Billion | -2.09pp |
| 2016-03-31 | -0.35% | ₹-81.68 Million | ₹23.03 Billion | +3.48pp |
| 2015-03-31 | -3.84% | ₹-706.89 Million | ₹18.43 Billion | -- |